期刊
BRITISH JOURNAL OF HAEMATOLOGY
卷 146, 期 6, 页码 652-655出版社
WILEY-BLACKWELL
DOI: 10.1111/j.1365-2141.2009.07775.x
关键词
bortezomib; follicular lymphoma; mantle cell lymphoma; non-Hodgkin lymphoma; proteasome inhibitor
类别
资金
- NCI Phase II [UO1 CA 69913]
- CTEP
- Lymphoma Research Foundation for Mantle Cell Lymphoma
P>Twice-weekly bortezomib has proven activity in mantle cell (MCL) and indolent lymphomas. This study explored a weekly schedule of bortezomib in follicular lymphoma (FL) and MCL. Although weekly bortezomib was better tolerated, the overall response rate (ORR) was inferior (18% vs. 50%, P = 0 center dot 02) with no complete remissions (CR) (compared with 18% CR for the twice-weekly schedule). Progression-free survival (PFS) was not different. The weekly schedule of bortezomib was less toxic, but yielded fewer and lower quality responses than twice-weekly bortezomib. Given the similar PFS, the weekly schedule may still be appropriate for some patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据